K. Gergory-Evans

K. Gregory-Evans, MD, PhD, FRCS, FRCOphth

Professor in Ophthalmology, Julia Levy BC Leadership Chair in Macular Research


Basic Info
The University of British Columbia
Eye Care Centre
2550 Willow Street
VancouverBC V5Z 3N9

Kevin Gregory Evans Clinic


Previous Appointments

1998-2009 | Reader in Molecular Ophthalmology
Imperial College London, London. UK

1997-1998 |  JW Kluge Research Fellow, (Foundation Fighting Blindness USA)
Professor R Weleber, Casey Eye Institute, Portland, OR, USA.

1995-1997 | Senior Registrar in Ophthalmology
Moorfields Eye Hospital, London, UK.

1994-1995 | Clinical Research Fellow, (Medical Research Council, UK)
Professor AC Bird, Institute of Ophthalmology, London, UK.


2013      Lang Medal, Royal Society of Medicine, UK.

2013      Foundation Fighting Blindness, ‘Recognition of Leadership’ Award



Retinal Therapeutics Lab

Novel molecular approaches in the treatment of retinal disease

In recent years a wealth of new information has become available on the causes of such retinal diseases as age-related macular degeneration, diabetic retinopathy and retinitis pigmentosa. This has generated an ideal environment to study new, molecular approaches to treating common retinal diseases. Additionally by combining treatments, potential synergies can be studied – more effective outcomes might be achieved by concurrently targeting multiple points of the pathogenic pathway. In a team approach using rodent, zebrafish and xenopus model systems, we are investigating such synergistic combination therapies, to correcting retinal cell apoptosis, protein misfolding and inflammation.

Cell-based therapeutics for age-related macular degeneration and retinitis pigmentosa

Cells can be used in two ways to repair damaged retina: to replace lost cells (tissue regeneration) or as vehicles to deliver drugs to the retina (a difficult undertaking because of the retina’s relative inaccessibility (e.g. the blood brain barrier prevents many drugs penetrating the retina). We are developing cell-based drug delivery techniques to allow for longer-term drug delivery and so avoid the need for repeated injections into the eye.

Molecular defects underlying retinal disease

Many of the commonest causes of retinal disease (e.g. macular degeneration, retinitis pigmentosa) arise from genetic abnormality. We continue to work on identifying the genes underlying retinal disease, as a means of developing better methods of diagnosis and more importantly to identify new therapeutic targets through a better understanding of disease pathogenesis.


G-banded ideogram of the human genome highlighting retinal dystrophy loci and diseases studied as part of this research program.

Clinical trial in retinal disease

Macular degeneration is the commonest cause of blindness in the western World. We are developing links with a number of pharmaceutical companies to trial new treatments for macular degeneration (e.g. photodynamic therapy, intra-vitreal anti-VEGF therapies).

Selected Publications
  1. Gregory-Evans CY, Wang X, Wasan K, Zhao J, Metcalfe AL, Gregory-Evans K. Manipulation of Pax6 dosage by topical nonsense suppression therapy reverses congenital ocular defects in the Sey mouse model. J Clin Invest. 2014; 214;111-116.
  2. Yanai A, Laver C, Joe AW, Viringipurampeer I, Wang X, Gregory-Evans CY, Gregory-Evans K. Optimized cell-handling of human embryonic stem cells in the differentiation of photoreceptor precursor cells. Tissue Eng Part C Methods 2013;19:755-764.
  3. Molday LL, Djajadi H, Yan P, Szczygiel L, Boye SL, Chiodo VA, Gregory-Evans K, Sarunic MV, Hauswirth WW, Molday RS. RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis type 12. Hum Mol Genet.2013;22:3894-3905.
  4. Evans CY, Po K, Shan X, Moritz OL, Gregory-Evans K. Focused magnetic stem cell targeting to the retina using superparamagnetic iron oxide nanoparticles. Cell Transplantation 2012; 21:1137-1148.
  5. Viringipurampeer IA, Ferreira T, DeMaria S, Yoon JJ, Shan X, Moosajee M, Gregory-Evans K, Ngai J, Gregory-Evans CY.Pax2 regulates a Fadd-dependent cellular switch that drives tissue fusion during eye development. Hum Mol Genet. 2012; 21:2357-2369.
Research Funding


Canadian Institutes of Health Research

Foundation Fighting Blindness (Canada)

Vision for Tomorrow Research Foundation (USA)

Sharon Stewart Research Fund

RHF Hearing Foundation

Crystal Family Trust


Original Research

1    Metcalfe A, Bashar AE, Gregory-Evans CY,Hafeli UO, Moritz OL, Sarunic MV, Douglas RM, Gregory-Evans K. Retinal neuroprotection using targeted systemic magnetic mesenchymal stem cells in the S334ter-4 transgenic rodent model of retinitis pigmentosa. Mol Vision 2014; Submitted.

2    Viringipurampeer IA, Shan X, Gregory-Evans K, Zhang JP, Mohammadi Z, Gregory-Evans CY.rip3 knockdown rescues photoreceptor cell death in blind pde6c zebrafish. Cell Death Differ 2014; In Press. Accepted 22 Nov. doi: 10.1038/cdd.2013.191 .

3    Yanai A, Laver C, Joe AW, Gregory-Evans K. Efficient Production of Photoreceptor Precursor Cells from Human Embryonic Stem Cells. Methods Mol Biol. 2014; In Press.

4  Gregory-Evans CY, Wang X, Wasan K, Zhao J, Metcalfe AL, Gregory-EvansK. Manipulation of Pax6 dosage by topical nonsense suppression therapy reverses congenital ocular defects in the Sey mouse model. J Clin Invest. 2014; 214;111-116.

5    Molday LL, Djajadi H, Yan P, Szczygiel L, Boye SL, Chiodo VA, Gregory-Evans K, Sarunic MV, Hauswirth WW, Molday RS. RD3 gene delivery restores guanylate cyclase localization and rescues photoreceptors in the Rd3 mouse model of Leber congenital amaurosis type 12. Hum Mol Genet.2013;22:3894-3905.

6    Yanai A, Laver C, Joe AW, Viringipurampeer I, Wang X, Gregory-Evans CY, Gregory-Evans K. Optimized cell-handling of human embryonic stem cells in the differentiation of photoreceptor precursor cells. Tissue Eng Part C Methods 2013;19:755-764.

7    Bashar AE, Metcalfe A, Yanai A, Laver C, Hafeli U, Gregory-Evans CY, Moritz OL, Matsubara JA, Gregory-Evans K. Influence of Iron Oxide Nanoparticles on Innate and Genetically Modified Secretion Profiles of Mesenchymal Stem Cells. IEEE Trans Mag. 2013;49:389-393.

8  Viringipurampeer IA, Ferreira T, DeMaria S, Yoon JJ, Shan X, Moosajee M, Gregory-Evans K, Ngai J, Gregory-Evans CY.Pax2 regulates a Fadd-dependent cellular switch that drives tissue fusion during eye development. Hum Mol Genet. 2012; 21:2357-2369.

9    Yanai A, Häfeli UO, Metcalfe AL, Soema P, Addo L, Gregory-Evans CL, Po K, Shan X, Moritz OL, Gregory-Evans K.Focused magnetic stem cell targeting to the retina using super-paramagnetic iron oxidenanoparticles. Cell Transplant. 2012; 21:1137-1148.

10  Schmouth, J-F, Banks KG, Mathelier A, Gregory-Evans CY, Castellarin M, Holt R, Gregory-Evans K, Wasserman WW, Simpson EM. Vision restored and brain abnormalities ameliorated by single-copy knock in of human NR2E1 in null mice. Mol Cell Biol. 2012;32:1296-1311.

11  Hamblion EL, Moore AT, Rahi JS; British Childhood Onset Hereditary Retinal Disorders Network Incidence and patterns of detection and management of childhood-onset hereditary retinal disorders in the UK. Br J Ophthalmol. 2012;96:360-365.

12  Gregory-Evans K, Po K, Chang F, Gregory-Evans CY. Pharmacological enhancement of ex vivo gene therapy neuroprotection in a rodent model of retinal degeneration. Ophthal Res 2012;47:32-38

13  McKeone R, Vieria H, Gregory‐Evans K, Gregory‐Evans CY, Denny P. Foxf2: A novel locus for anterior segment dysgenesis adjacent to the Foxc1 gene. PLoS One 2011;6:e25489.

14  Gregory-Evans K, Cheong-Leen, George SM, Xie J, Moosajee M, Colapinto P, Gregory-Evans CY. Non-invasive anterior segment and posterior segment optical coherence tomography and phenotypic characterization of aniridia. Can J Ophthalmol 2011;46:337-344.

15  Gregory-Evans CY, Moosajee M, Shan X, Gregory-Evans K.Gene-specific differential response to anti-apoptotic therapies inzebrafish models of ocular coloboma. Mol. Vision 2011; 17:1473-1484.

16  Gregory-Evans K, Rai P, Patterson J. Successful treatment of subretinal neovascularisation with intravitreal ranibizumab in a child with optic nerve head drusen. J Pediatr Ophthalmol Strabismus 2009; 46:e1-4.

17  Gregory-Evans K, Chang F, Hodges MD, Gregory-Evans CY. Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Mol Vision 2009; 15:962-73.

18  Harding SP, Tomlin K, Reeves BC, Langham J, Walker J, Carpenter J, Grieve R, Patton WP, Muldrew KA, Peto T, Chakravarthy U; Verteporfin Photodynamic Therapy Cohort Study Group.Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes. Ophthalmol. 2009;116:e1-8

19  Moosajee M, Gregory-Evans K, Ellis CD, Seabra MC, Gregory-Evans CY. Translational bypass of nonsense mutations in zebrafish rep1, pax2.1 and lamb1 highlights a viable therapeutic option for untreatable genetic eye disease. Hum Mol Genet. 2008;17:3987-4000.

20  Guerin K, Gregory-Evans CY, Hodges MD, Moosajee M, Mackay DS, Gregory-Evans K, Flannery JG. Translational modification of nonsense mutations in rodent models of retinitis pigmentosa. Exp Eye Res. 2008;87:197-207.

21  Zaidi FH, Hull JT; Pierson SN, Wulff K, Aeschbach D, Gooley JJ, Brainard GC, Gregory-Evans K, Rizzo III JF, Czeisler CA, Foster RG, Moseley MJ, Lockley SW. Short-wavelength light sensitivity of circadian, pupillary and visual awareness in ‘blind’ humans lacking a functional outer retina. Curr. Biol. 2007; 17, 2122-2128.

22  Gregory-Evans CY, Moosajee M, Hodges MD, Mackay DS, Game L, Bloch-Zupan A, Rüschendorf F, Santos-Pinto L, Wackens G, Gregory-Evans K. SNP genome scanning localises oto-dental syndrome to chromosome 11q13 and microdeletions at this locus implicate FGF3 in dental and inner ear disease and FADD in ocular coloboma. Hum Mol Genet. 2007;16:2482–2493.

23  Zaidi FH, Bremner FD, Gregory-Evans K, Cocker KD, Moseley MJ. Subretinal membranes are associated with abnormal degrees of pupil “evasion”: an index of clinical macular dysfunction. Br J Ophthalmol. 2006;90:1115-1118.

24   Michaelides M, Jenkins SA, Brantley MA, Andrews RM, Waseem N, Luong V, Gregory-Evans K, Bhattacharya SS, Fitzke FW, Webster AR. Maculopathy due to the R345W substitution in fibulin-3: Distinct clinical features, disease variability, and extent of retinal dysfunction. Invest Ophthalmol Vis Sci. 2006:47:3085-3097.

25   Burton BJL, Holder GE, Duguid G, Gregory Evans K.Optical coherence tomography findings in benign concentric annular dystrophy. Eye 2005;19:699-701.

26   Zaidi FH, Gregory-Evans K, Acheson JF, Ferguson V. Familial Bell’s palsy in females: a phenotype with a predilection for eyelids and lacrimal gland. Orbit 2005;24:121-124.

27   Pathai S, Gregory-Evans K. Photoessay: Pigmentary retinopathy. Eye News 2004;10:6:59.

28   Gregory-Evans CY,Vieira H, Dalton R, Salt A, Adams GGW, Gregory-Evans K. Ocular coloboma and high myopia with Hirschsprung disease caused by a novel ZFHX1B mutation. Am J Med Genet 2004;131:86-90.

29   Arora A, Wren S, Gregory Evans K. Desferrioxamine Related Maculopathy: A Case Report. Am J Hematol. 2004;76:386-388.

30   Toomes C, BottomleyHM, Jackson RM, Towns KV, Scott S, Mackey DA, Craig JE, Jiang L, Yang Z, Trembath R, Woodruff G, Gregory-Evans CY, Gregory-Evans K, Parker MJ, Black GCM, Downey LM, Zhang K, Inglehearn CF. Mutations in LRP5 or FZD4 underlie the common FEVR locus on chromosome 11q. Am J Hum Genet. 2004;74:721-730.

31   Zaidi F, Cheong-Leen R, Gair EJ, Wier R, Sharkawi E, Lee N, Gregory-Evans K. The Amsler chart is of doubtful value in retinal screening for early laser therapy of subretinal neovascularisation. A London-based survey. Eye 2004; 18:503-508

32   Zaidi F, Gair EJ, Gregory-Evans K. Criteria for improving visual acuity in ischaemic branch retinal vein occlusion using argon laser. Eye 2004: 18:316-8.

33   Ramalho JS, Gregory-Evans K, Huxley C, Seabra MC. Mouse genetic corneal disease resulting from transgenic insertional mutagenesis. Br J Ophthalmol. 2004;88:428-432.

34   Blackburn J, Tarttelin EE, Gregory-Evans CY, Moosajee M, Gregory-Evans K. Transcriptional regulation and expression of the ‘dominant drusen’ gene FBLN3 (EFEMP1) in mammalian retina. Invest Ophthalmol Vis Sci 2003;44:4613-4621.

35   Bellingham J, Fox MF, Gregory-Evans K, Gregory-Evans CY. Gene structure and tissue expression of human selenoprotein W (SEPW1), and identification of a retroprocessed pseudogene, SEPW1PBiochem Biophys Acta 2003;1627:140-146.

36   Wong SC, Fong CSK, Lee N, Gregory-Evans CY, Gregory-Evans K. Successful photodynamic therapy for subretinal neovascularisation due to Sorsby’s fundus dystrophy with – one year follow up. Br J Ophthalmol. 2003;87:796-7.

37   Tarttelin EE, Bellingham J, Foster JG, Hankins MW, Bibb LC, Gregory-Evans K, Gregory-Evans CY, Wells DJ, Lucas RJ. Expression of opsin genes early in ocular development of humans and mice. Exp Eye Res 2003; 76:393-6.

38   Hodges M, Vieira H, Gregory-Evans K, Gregory-Evans CY. Characterisation of the genomic and transcriptional structure of the CRX gene: substantial differences between the human and mouse genes. Genomics 2002;80:531-542.

39   Vieira H, Gregory-Evans K, Lim N, Brookes JL, Brueton LA, Gregory-Evans CY. First genomic localization of oculo-oto-dental syndrome, linkage to chromosome 20q13.1. Invest Ophthalmol Vis Sci 2002;43:2540-2545.

40   Sarangapani S, Chang L, Gregory-Evans K. Cataract surgery in Senior-Loken syndrome is beneficial despite severe retinopathy. Eye 2002; 16:782-5.

41   Talks SJ, Ebenezer N, Hykin P, Adams G, Yang F, Schulenburg WE, Gregory-Evans K, Gregory-Evans CY. Mutations in the 5’ regulatory region of the Norrie’s disease gene in retinopathy of prematurity. J Med Genet. 2001; 38: e46

42  Bibb LC, Holt JKL, Tarttelin EE, Hodges MD, Gregory-Evans K, Rutherford A, Lucas RJ, Sowden JC, Gregory-Evans CY. Temporal and spatial expression patterns of the CRX transcription factor and its downstream targets. Critical differences during human and mouse eye development. Hum Mol Genet. 2001; 10: 1571-1579.

43   Tarttelin EE, Gregory-Evans CY, Bird AC, Weleber RG, Klein ML, Blackburn J, Gregory-Evans K. Molecular genetic heterogeneity in autosomal dominant drusen. J Med Genet. 2001; 38: 381-384.

44   Gregory-Evans K, Kelsell RE, Gregory-Evans CY, Downes SM, Fitzke FW, Holder GE, Simunovic M, Mollon JD, Taylor R, Hunt DM, AC Bird, Moore AT. Autosomal dominant cone-rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase. Ophthalmol. 2000; 107: 55-61.

45   Small W, Yelchits S, Udar N, Klein R, Garcia C, Gallardo G, Puech B, Puech V, Saperstein D, Lim J, Flaxell C, Weber B, Sauer C, Kelsell RE, Hunt DM, Gregory-Evans K, Lennon F, Periack-Vance M. North Carolina macular dystrophy (MCDR1) locus: a fine resolution genetic map and haplotype analysis. Mol. Vision 1999; 5:38.

46   Tarttelin EE, Kirschner LS, Bellingham J, Baffi J, Taymans SE, Gregory-Evans K,Csaky K, Stratakis CA, Gregory-Evans CY. Cloning and characterisation of a novel orphan G protein-coupled receptor localised to human chromosome 2p16. Biochem. Biophys. Res. Com. 1999, 260:174-180.

47   Kermani S, Gregory-Evans K, Tarttelin EE, Bellingham J, Fox M, Plant C, Bhattacharya SS, Gregory-Evans CY. Refined genetic and physical positioning of the Doyne honeycomb retinal dystrophy (DHRD) gene. Hum Genet. 1999; 104: 77-82.

48   Reichel MB, Kelsell RE, Fan J, Gregory CY, Evans K, Moore AT, Hunt MD, Fitzke FW, Bird AC. Phenotype of a British North Carolina macular dystrophy family linked to chromosome 6q. Br J Ophthalmol. 1998; 82: 1162-1168.

49   Bellingham J, Gregory-Evans K, Gregory-Evans CY. Sequence and tissue expression of a novel human carbonic anhydrase-related protein, CARP-2, mapping to chromosome 19q13.3. Biochem. Biophys. Res. Com. 1998; 253: 364-367.

50   Kelsell RE, Gregory-Evans K, Gregory-Evans CY, Holder GE, Jay MR, Weber BHF, Bird AC, Moore AT, Hunt DM. Localization of a gene (CORD7) for a dominant cone-rod dystrophy to chromosome 6q. Am J Hum Genet 1998,63:274-279.

51   Gregory-Evans K, Fariss RN, Possin DE, Gregory-Evans CY, Milam AH. Abnormal cone synapses in human cone-rod dystrophy. Ophthalmol 1998, 105:2306-2312.

52   Bellingham J, Gregory-Evans K, Gregory-Evans CY. Mapping of human interferon regulatory factor 3 (IRF3) to chromosome 19q13.3-13.4 by an intragenic polymorphic marker. Ann Hum Genet. 1998,62:231-234.

53   Bellingham J, Gregory-Evans CY, Gregory-Evans K. Microsatellite markers for the cone-rod retinal dystrophy gene, CRX, on 19q13.3. J Med Genet 1998,35:527.

54   Kelsell RE, Gregory-Evans K, Payne AM, Perrault I, Kaplan J, Yang R-B, Garbers DL, Bird AC, Moore AT, Hunt DM. Mutations of retinal guanylate cyclase (RETGC-1) gene in dominant cone-rod dystrophy. Hum Mol Genet 1998,7:1179-1184.

55   Bellingham J, Gregory-Evans K, Gregory-Evans CY. A polymorphic dinucleotide repeat in the 5′ flanking region of the human interleukin 11(IL11) gene. Immunogenet. 1998,47:499-500.

56   Bellingham J, Wijesuriya SW, Evans K, Fryer A, Lennon C, Gregory CY. Genetic and physical localisation of the gene causing cone-rod dystrophy (CORD2). In Degenerative Retinal Diseases. Plenum Press, New York, 1997, 295-302.

57   Evans K, Gregory CY, Kermani S, Wijesuriya SW, Jay MR, Plant C, Bird AC. Doyne’s honeycomb retinal degeneration. Range of ocular phenotype. Arch Ophthalmol 1997, 115:904-910.

58   Kelsell RE, Evans K, Gregory CY, Moore AT, Bird AC, Hunt DM. Localisation of a gene for autosomal dominant cone-rod retinal dystrophy (CORD6) to chromosome 17p12-p13. Hum Mol Genet 1997, 6:597-600.

59   Al-Maghtheh MG, Vithana E, Tarttelin E, Jay MR, Evans K, Moore AT, Bhattacharya SS, Inglehearn CF. Evidence for a major retinitis pigmentosa locus on 19q13.4 (RP11) and association with a unique bimodal expressivity phenotype. Am J Hum Genet 1996, 59:864-871.

60   Jay MR, Plant C, Evans K, Gregory CY. Doyne’s Revisited. Eye 1996, 10:469-472.

61  Gregory CY, Evans K, Wijesuriya S, Kermani S, Jay MR, Plant C, Cox N, Bird AC, Bhattacharya SS. The gene responsible for autosomal dominant Doyne’s honeycomb retinal dystrophy (DHRD) maps to chromosome 2p16. Hum Mol Genet 1996, 5:1055-1059

62   Godley BF, Tiffin PAC, Evans K, Kelsall RE, Hunt DM, Bird AC. Clinical features of Progressive Bifocal Chorioretinal Atrophy (PBCRA): a retinal dystrophy linked to chromosome 6q. Ophthalmology 1996, 103:893-898.

63 Wijesuriya S, Evans K, Jay M, Davidson C, Weber BHF, Bird AC, Bhattacharya SS, Gregory CY. ­Sorsby’s fundus dystrophy in the British Isles: demonstration of a striking founder effect by microsatellite generated haplotypes Genome Res 1996, 6:92-101.

64   Kelsell RE,Godley BF, Evans K, Tiffin PAC, Gregory CY, Plant C, Moore AT, Bird AC, Hunt DM. Localisation of the gene for progressive bifocal chorioretinal atrophy (PBCRA) to chromosome 6q. Hum Mol Genet 1995, 4:1653-1656.

65   Evans K, Gregory CY, Wijesuriya S, Jay M, Bird AC, Bhattacharya SS. Molecular genetic studies in retinal dystrophies that principally affect the macula. In Degenerative diseases of the retina. Plenum Press, New York, 1995, 323-330.

66   Evans K, Al-Maghtheh MG, Fitzke FW, Moore AT, Jay M, Inglehearn CF, Arden GB, Bird AC. Bimodal expressivity in autosomal dominant retinitis pigmentosa genetically linked to chromosome 19q. Br J Ophthalmol 1995, 79:841-846.

67   Gregory CY, Wijesuriya S, Evans K, Jay M, Bird AC, Bhattacharya SS.Linkage refinement localises Sorsby fundus dystrophy between markers D22S275 and D22S278. J Med Genet 1995, 32:240-241.

68   Gregory CY, Evans K, Bhattacharya SS. Genetic refinement of the chromosome 5q lattice corneal dystrophy type I locus to within a two centimorgan interval. J Med Genet 1995, 32:224-226.

69   Evans K, Duvall-Young J, Fitzke FW, Arden GB, Bird AC. Chromosome 19q cone-rod retinal dystrophy. Ocular phenotype. Arch Ophthalmol 1995, 113:195-201.

70   Holz FG, Evans K, Gregory CY, Bhattacharya SS, Bird AC. Autosomal dominant macular dystrophy simulating North Carolina macular dystrophy. Arch Ophthalmol 1995, 113:178-184.

71   Evans K, Gregory CY, Fryer A, Whittaker J, Duvall-Young J, Bird AC, Bhattacharya SS.The role of molecular genetics in the prenatal diagnosis of retinal dystrophies. Eye 1995, 9:24-28.

72   Gregory CY, Evans K, Fryer A, Whittaker J, Weissenbach J, Bhattacharya SS. Linkage refinement of the cone-rod retinal dystrophy locus on chromosome 19q. Am J Hum Genet 1994, 55:1061-1063.

73   Al-Maghtheh MG, Inglehearn CF, Keen TJ, Evans K, Moore AT, Jay M, Bird AC, Bhattacharya SS. Identification of a sixth locus for autosomal dominant retinitis pigmentosa on chromosome 19. Hum Mol Genet 1994, 3:351-354.

74 Evans K, Fryer A, Inglehearn CF, Duvall-Young J, Whittaker J, Gregory CY, Butler R, Ebenezer N, Hunt DM, Bhattacharya SS. Genetic linkage of cone-rod retinal dystrophy to chromosome 19q and evidence for segregation distortion. Nature Genet 1994, 6:210-213.

75  Evans K, O’Brien C, Patterson A. Corneal endothelial response to corticosteroid in cataract surgery. Eur J Implant Ref Surg 1994, 6:74-78.

76  Evans K. Intraocular pressure measurement in children. Ophthal Physiol Optics 1993, 13: 219-221.

77  Evans K, Wishart PK, McGalliard J. Neovascular complications after central retinal vein occlusion. Eye 1993, 7: 520-524.

79  Evans K, Hickey-Dwyer MU. Bifid anterior segment with maternal hypervitaminosis A. Br J Ophthalmol 1991, 11: 691-692.

80  Evans K. Uncorrected refractive error in a hospital population. J Ophth Physiol Optics 1987, 7: 245-247.


Published letters

  1. Zaidi FH, Gair EJ, Lee N, Gregory-Evans K. More than meets the eye: alternatives to black-on-white visual field testing. Eye. 2006;20:508-509
  2. Zaidi FH, Gregory-Evans K. Replacing the Amsler grid. Ophthalmology. 2005 Feb;112(2):357


Review articles & book chapters

  1. Viringipurampeer IA, Bashar AE, Gregory-Evans CY, Moritz OL, Gregory-Evans K. Targeting inflammation in emerging therapies for genetic retinal disease. Int J Inflamm. 2013;2013:581751.
  2. Gregory-Evans CY, Wallace VA, Gregory-Evans K. Gene networks: dissecting pathways in retinal development and disease. Prog Retin Eye Res2013;33:40-66.
  3. Gregory-Evans K, Bashar AE, Laver C. Use of magnetism to enhance cell transplantation success in regenerative medicine. Regen Med. 2013; 8:1-3.
  4. Gregory-Evans K, Bashar E, Tan M. Ex vivo gene therapy and vision. Curr Gene Ther2012:12:103-115.
  5. Gregory-Evans CY, Gregory-Evans K. Foveal hypoplasia, the case for arrested development. Expert Rev Ophthalmol 2011:6;565-574.
  6. Gregory-Evans K, Pennesi M, Weleber RG. (eds: Stephen J. Ryan, David R. Hinton,; Andrew P. Schachat, Pat Wilkinson) (Dec 2011) “Retinitis pigmentosa and allied disorders” Retina volume 1 pp. Section 6, Chapter 17 Mosby, Inc., St Louis, Missouri, USA.
  7. Gregory-Evans K, Joe AW. Mesenchymal stem cells and potential applications in treating ocular disease. Curr Eye Res 2010; 35:941-52.
  8. Hodges MD, Gregory-Evans CY, Gregory-Evans K. A clearer view of stem cells in retinal disease. In ‘Stem Cell Repair and Regeneration’ (N. Levicar et al. eds) Vol 3; Ch 13; 2007.
  9. Weleber RG, Gregory-Evans K. (eds: Stephen J. Ryan, David R. Hinton,; Andrew P. Schachat, Pat Wilkinson) (September 2005) “Retinitis pigmentosa and allied disorders” Retina volume 1 pp. Section 6, Chapter 17 Mosby, Inc., St Louis, Missouri, USA  (ISBN: 0323025986).
  10. Gregory-Evans CY, Williams MJ, Halford S, Gregory-Evans K. Ocular coloboma: a reassessment in the age of molecular neuroscience. J Med Genet. 2004;41:881-91.
  11. Hodges MJ, Bibb LC, Tarttelin EE, Gregory-Evans K, Gregory-Evans CY. (2001) Characterisation and expression studies of the human CRX gene. In “New Insights into Retinal Degenerative Diseases” Eds RE Anderson, MM LaVail and JG Hollyfield. Pp 71-86, Plenum Press, New York.
  12. Gregory-Evans K. Clinical Genetics. Key Topics in Ophthalmology, Bios Scientific Publishers Ltd., Oxford 2001, 66-68.
  13. Gregory-Evans K. Developmental disorders of the globe.Ophthalmology monographs: Paediatric Ophthalmology (Ed AT Moore)2000, 53-61.
  14. Malhotra R, Gregory-Evans K. Management of ocular ischaemic syndrome. Br J Ophthalmol. 2000; 84: 1428-31.
  15. Weleber RG, Gregory-Evans K.Retinitis pigmentosa and allied disorders. Retina. CV Mosby, St Louis 2000, 362-460.
  16. Malhotra R, Gregory-Evans K. The management of ocular ischaemic syndrome. CME   Journal Ophthalmology. 2000: 4; 1-28.
  17. Gregory-Evans K. What is Sorsby’s fundus dystrophy? Br J Ophthalmol. 2000, 82:72-76.
  18. Gregory-Evans K, Gregory-Evans CY. The role of CRX-transcription factor in retinal degeneration. Retina Int. Sci. Newsletter, 1999, http://www.irpa.org/sci-news/topgreg.htm.
  19. Gregory-Evans K, Bird AC. Hereditary pigmentary retinal and macular dystrophies. Oxford Textbook of Ophthalmology (Eds. Easty & Sparrow) Oxford Medical Publication, Oxford. 1999, 2.9.5:607-612.
  20. Evans K, Bhattacharya SS. Retinal dystrophies: a molecular genetic approach. Genetic mapping of disease genes. Academic Press Ltd, London. 1997:247-254.
  21. Gregory-Evans K. Molecular biology for ophthalmologists. Eye News 1999,5;5:6-14.
  22. Gregory-Evans K, Bhattacharya SS. Genetic blindness: current concepts in the pathogenesis of human outer retinal dystrophies. Trends in Genetics 1998. 14:103-108.
  23. Moore AT, Evans K. Inherited macular dystrophies. Pediatric Ophthalmology. 2nd Ed. London, Blackwell, 1997:595-609.
  24. Gregory-Evans K, Weleber RG. An Eye for an Eye: new models of genetic ocular disease. Nature Biotechnology 1997,15:947-948.
  25. Moore AT, Evans K. The molecular genetics of central retinal dystrophies. Aus NZ J Ophthalmol 1996, 24:189-198.
  26. Jay MR, Evans K. Retinal dystrophies and genetic counselling. Acta Opthalmol Scand 1996, 219(Suppl);74:5-7.
  27. Evans K, Bird AC. The genetics of complex ophthalmic disorders. Br J Ophthalmol 1996, 80:763-768.
Professional Activities

Internal committees

VCHRI Research Infrastructure Working Group.
Chairman. 2011-present

VCHRI Council
Member, 2011-present

BC Stem Cell and Regenerative Medicine Steering Group
Member, 2012-present

External committees

Professional Standards, Royal College of Ophthalmologists, United Kingdom.
AMD Advisory Sub-Committee. 2007-2009

Examinations, Royal College of Ophthalmologists, United Kingdom.
Examiner. 2006 -2010

Canadian Institute of Health Research (Canada):
Team Grant Review Panel. 2009-present

Californian Institute for Regenerative Medicine (USA):
Grant Review Panel. 2010-present

Foundation Fighting Blindness (Canada)
Director, 2012-present

Pfizer Pharmaceuticals Stem Cell Advisory Panel
Member, 2012-present


Medical Research Council, MRC Clinical Fellow, Moorfields Eye Hospital, London.
Foundation Fighting Blindness, Casey Eye Institute, Portland, Oregon, USA, FY98 JW Kluge Research Fellow.
Royal College of Ophthalmologists, Fellow.
Royal College of Physicians and Surgeons, Glasgow, Fellow.

Guest lectures

Disease reversal using nonsense suppression in animal models of eye disease. PTC Therapeutics Inc. Advisory Committee Meeting, New Jersey, USA. 2014

Translational pharmaceuticals in retinal disease. Keynote Speaker, Royal Society of Medicine, London, UK. 2013

A clinical trial in Aniridia. Aniridia International Annual Research Conference, University of Virginia, USA. 2013

Focused Magnetic Stem Cell Targeting to the Retina Using Magnetic Nanoparticles Keynote Speaker, 9th International Conference on the Scientific and Clinical Applications of Magnetic Carriers, University of Minnesota, Minneapolis, USA. 2012.

Pharmaceutical therapy for Macular Degeneration Guest Faculty, Form and Function in Ocular Disease Symposium, Dalhousie University, Halifax, Canada. 2012

Cell therapy in macular degeneration Annual Retina Axis Meeting of the Vision Network of Quebec, Montreal, Canada. 2012

The continued promise of gene therapy in macular degeneration. Keynote speaker: Heart, Lung & Blood Research and Education FEST, Vancouver, Canada. 2010.

Contemporary views on stem cells and eye disease. Royal College of Ophthalmologists Annual Congress, UK. 2009.

Related Links